1-(2-hexyloxyphenyl)ethanone | 7191-40-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-hexyloxyphenyl)ethanone
• 英文别名: 2-Hexyloxy-acetophenon；1-(2-Hexoxyphenyl)ethanone
• CAS: 7191-40-4
• 化学式: C₁₄H₂₀O₂
• 分子量: 220.312
• InChiKey: QCQRDQXUCCYINJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-hexyloxyphenyl)ethanone 在 盐酸羟胺 、 sodium ethanolate 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 52.75h， 生成 N-(1-adamantyl)-5-(2-hexyloxyphenyl)isoxazole-3-carboxamide
  参考文献：
  名称：

  3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

  摘要：

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.010
• 作为产物：
  描述：

  溴己烷 、 2'-羟基苯乙酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以59%的产率得到1-(2-hexyloxyphenyl)ethanone
  参考文献：
  名称：

  3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

  摘要：

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.010

文献信息

• SKIN WHITENING AGENT CONTAINING NOVEL CYCLIC COMPOUND
  申请人：RNS CO.,LTD.

  公开号：US20160221921A1

  公开（公告）日：2016-08-04

  Provided is a derivative or a polyhydroxy cyclic compound represented by Formula I or a pharmacologically acceptable salt thereof with excellent whitening effects, comprising; wherein circle around (A)} is derived from an aromatic cyclic compound, B is hydrogen, oxo (═O), amino (—NH 2 ), imino (═NH), or a saturated or unsaturated straight or branched alkyl, alkoxy, monoalkylamino, or dialkylamino group having 1 to 10 carbon atoms, C n , C n+1 and C n+2 are three neighboring carbon atoms present in the aromatic cyclic compound, wherein n is a positive integer, R 1 is hydrogen, hydroxy, or a saturated or unsaturated straight or branched alkyl or alkoxy group, X and Y are selected from a group consisting of hydrogen, hydroxy, and a saturated or unsaturated straight or branched alkoxy, or acyloxy group, and one of X and Y is hydrogen, R 2 , R 3 , R 4 and R 5 are each independently at least one substituent selected from a group consisting of hydrogen, alkyl, alkoxy, acyloxy, acyloxymethyl, oxo, hydroxy, vinyl, nitrile, carboxaldehyde, carbonitrile and aldehyde.

  提供的是一种由化学式I表示的衍生物或多羟基环化合物，或其药理学上可接受的盐，具有出色的美白效果，包括；其中圆圈A}源自芳香环化合物，B为氢、氧化物(═O)、氨基(—NH2)、亚胺基(═NH)或具有1至10个碳原子的饱和或不饱和直链或支链烷基、烷氧基、单烷基氨基或二烷基氨基基团，Cn、Cn+1和Cn+2是芳香环化合物中存在的三个相邻碳原子，其中n为正整数，R1为氢、羟基或饱和或不饱和直链或支链烷基或烷氧基，X和Y从氢、羟基和饱和或不饱和直链或支链烷氧基或酰氧基组成的一组中选择，并且X和Y中的一个为氢，R2、R3、R4和R5分别独立地至少为来自氢、烷基、烷氧基、酰氧基、酰氧甲基、氧化物、羟基、乙烯基、腈基、羧醛基、碳腈基和醛基的取代基组成的一组中的至少一种取代基。
• Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients
  申请人：Delhomel Francois Jean

  公开号：US20070032543A1

  公开（公告）日：2007-02-08

  The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives and combinations of said derivatives with other therapeutically active ingredients. The invention also concerns compositions comprising said derivatives or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathology related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing.

  本发明涉及新的取代的1,3-二苯基丙烯酮衍生物以及该衍生物与其他治疗活性成分的组合物。本发明还涉及包含该衍生物或该组合物的组合物，以及用于治疗脑血管疾病、与炎症相关的病理学、神经退行性、脂质和/或葡萄糖代谢紊乱、细胞增殖和/或分化和/或皮肤或中枢神经系统衰老的用途。
• US7566737B2
  申请人：——

  公开号：US7566737B2

  公开（公告）日：2009-07-28
• 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis
  作者：Aurélien Tourteau、Virginie Andrzejak、Mathilde Body-Malapel、Lucas Lemaire、Amélie Lemoine、Roxane Mansouri、Madjid Djouina、Nicolas Renault、Jamal El Bakali、Pierre Desreumaux、Giulio G. Muccioli、Didier M. Lambert、Philippe Chavatte、Benoît Rigo、Natascha Leleu-Chavain、Régis Millet

  DOI：10.1016/j.bmc.2013.06.010

  日期：2013.9

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.